Market Place
Sourcing Support
Alto Neuroscience Reports Q3 2024 Results & Business Highlights
12 Nov 2024 //
BUSINESSWIRE
Alto’s midphase depression trial falls flat
23 Oct 2024 //
FIERCE BIOTECH
Alto Publishes Study on Cognitive Performance and Antidepressants
04 Sep 2024 //
BUSINESSWIRE
Alto Neuroscience to Participate in Upcoming Investor Conferences
03 Sep 2024 //
BUSINESSWIRE
Alto Neuroscience Reports Q2 2024 Results And Business Highlights
13 Aug 2024 //
BUSINESSWIRE
Alto Neuroscience Gets Wellcome Trust Funding For ALTO-100 Development
25 Jul 2024 //
BUSINESSWIRE
Alto Neuroscience Completes Enrollment For ALTO-100 MDD Phase 2b Study
16 Jul 2024 //
BUSINESSWIRE
Amit Etkin Named EY Entrepreneur Of The Year® 2024 Bay Area Award Winner
18 Jun 2024 //
BUSINESSWIRE
Alto Neuroscience to Present at the Jefferies Global Healthcare Conference
29 May 2024 //
BUSINESSWIRE
Alto Neuroscience Appoints Michael Hanley as Chief Operating Officer
21 May 2024 //
BUSINESSWIRE
Alto Neuroscience Reports Q1 2024 Results, Business Highlights
14 May 2024 //
BUSINESSWIRE
Alto Neuroscience Pipeline, Platform Data At Conferences
09 May 2024 //
BUSINESSWIRE
Alto Neuroscience Announces Positive Phase 1 Data for ALTO-101
23 Apr 2024 //
BUSINESSWIRE
Alto Neuro Announces Initiation of Ph 2 Study of ALTO-203 in Patients with MDD
03 Apr 2024 //
BUSINESSWIRE
Alto Neuroscience Reports Full Year 2023 Financial Results
21 Mar 2024 //
BUSINESSWIRE
Alto Neuroscience Appoints Maha Radhakrishnan, M.D., to Board of Directors
11 Mar 2024 //
BUSINESSWIRE
Alto Neuroscience to Participate in Upcoming Investor Conferences
07 Mar 2024 //
BUSINESSWIRE
Alto Neuroscience to Present at the TD Cowen 44th Annual Healthcare Conference
27 Feb 2024 //
BUSINESSWIRE
Alto Neuroscience Announces Closing of Upsized Initial Public Offering
06 Feb 2024 //
BUSINESSWIRE
Alto, Fractyl head to public markets with IPOs north of $100M
02 Feb 2024 //
FIERCE BIOTECH
Alto Neuroscience Announces Pricing of Upsized Initial Public Offering
01 Feb 2024 //
BUSINESSWIRE
Alto Neuroscience preps IPO to push CNS therapies through clinic
16 Jan 2024 //
FIERCE BIOTECH
Mid-stage CNS biotech Alto Neuroscience files for NYSE listing
15 Jan 2024 //
ENDPTS
Alto Neuroscience Announces Data from Presentations at the 62nd Annual Meeting
07 Dec 2023 //
BUSINESSWIRE
Alto`s 2nd precision psychiatry med improves depression symptoms
05 Dec 2023 //
FIERCE BIOTECH
Alto`s precision depression drug shows positive results in Phase II study
05 Dec 2023 //
BUSINESSWIRE
Alto Neuroscience Announces Positive Results from Phase 2 Study of ALTO-300
04 Dec 2023 //
BUSINESSWIRE
Alto Neuroscience Closes $45 Million in Oversubscribed Series C Financing
21 Nov 2023 //
BUSINESSWIRE
Alto Neuroscience Appoints Andrew Dreyfus to Its Board of Directors
18 Oct 2023 //
BUSINESSWIRE
Alto Neuroscience Announces Positive Results from Phase 2 Study of ALTO-100
26 Sep 2023 //
BUSINESSWIRE
Alto Neuroscience to Participate in Upcoming Investor Conferences
12 Sep 2023 //
BUSINESSWIRE
Alto Neuroscience to Present at the Stifel 2023 CNS Days
28 Mar 2023 //
BUSINESSWIRE
Alto Neuro CEO, Amit Etkin to Participate in National Academies of Sciences
07 Mar 2023 //
BUSINESSWIRE
Alto Neuroscience to Present at Oppenheimer 33rd Annual Healthcare Conference
06 Mar 2023 //
BUSINESSWIRE
Erin R. McQuade, J.D., Joins Alto as General Counsel and CAO
07 Feb 2023 //
BUSINESSWIRE
Alto Neuroscience Announces $60 Million in Additional Financing
30 Jan 2023 //
BUSINESSWIRE
Alto Neuroscience bags $25M for four Phase II drugs
30 Jan 2023 //
ENDPTS
Alto’s hopes for brain biomarker strategy rise on phase 2 data
11 Jan 2023 //
FIERCE BIOTECH
Alto Neuroscience to Present at 41st Annual J.P. Morgan Healthcare Conference
23 Dec 2022 //
BUSINESSWIRE
Alto Announces Data from PI Evaluating Brain Effects of Drug Combinations
14 Dec 2022 //
BUSINESSWIRE
Alto Neuroscience Presents New Data Leveraging EEG and Machine Learning
08 Dec 2022 //
BUSINESSWIRE
Alto Neuroscience Announces $35 Million Series B Financing
25 Oct 2022 //
BUSINESSWIRE
Alto continues march toward the clinic with Series B, hoping to unveil data
25 Oct 2022 //
ENDPTS
Alto to Participate in Annual Novel Mechanisms in Neuropsychiatry Summit
16 Sep 2022 //
BUSINESSWIRE
Alto Neuroscience CEO, Amit Etkin, M.D., Ph.D., Appointed to NIDA’s NACDA
12 May 2022 //
BUSINESSWIRE
Industry Veteran Mikael Eliasson Joins Alto Neuroscience as COO
12 Apr 2022 //
BUSINESSWIRE
Cerebral and Alto Neuroscience Enter into Strategic Collab to Launch First-Ever
16 Dec 2021 //
BIOSPACE
Cerebral, Alto Neuroscience Collaborate to Launch Study in Precision Psychiatry
16 Dec 2021 //
BUSINESSWIRE
